- Advertising
- Asia
- Bangladesh
- Biological Inventions
- BRAND VALUATION
- China
- Comparative Advertisement
- Copyright
- Copyright Infringement
- Copyright Litigation
- Counterfeiting
- Covid
- Data Protection
- Design
- Digital Marketing Rights
- DRM
- Electronics
- Geographical Indication
- India
- Indian Patents Act
- Indonesia
- Intellectual Property
- Interim Injunction
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Japan
- Legal Issues
- Licensing
- Malaysia
- Myanmar
- NCLT
- NEPAL
- Net Neutrality
- News & Updates
- Office
- Patent Commercialisation
- Patent Cooperation Treaty
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Opposition
- Patent Prosecution
- Patent Rule Amendment
- Patent Term Extension
- Patents
- pharma
- Philippines
- Punitive Damages
- Section 3(D)
- section 64
- Singapore
- South-east Asia
- Technology
- Technology Transfer
- Thailand
- Trademark
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
Patenting of a Drug Under IPR.
December 9, 2022 - 11:19 am
Categories:
drug
pharma
Pharma- biotech- Patent Commercialisation
2 Comments INTRODUCTION This particular blog is on the subject matter that how a drug patent can be obtained under the patent law in India and in this context the landmark judgement of the Supreme court- Novartis v. Union of India has been covered in this blog. In this blog the various facets with respect to getting … Continue reading Patenting of a Drug Under IPR.
Read more »Sun Pharma and Celegene Settle Patent Dispute over Lenalidomide (Revlimid®)
Settling an over three old patent infringement dispute, Indian pharmaceutical major, Sun Pharmaceuticals and its subsidiary, including US subsidiary (“Sun”), has reached a settlement with Celgene Corporation (“Celgene”), a subsidiary of pharmaceutical major Bristol Myers Squibb (BMS), to resolve and settle the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a … Continue reading Sun Pharma and Celegene Settle Patent Dispute over Lenalidomide (Revlimid®)
Read more »Bajaj Healthcare Files Compulsory License with Indian Patent Office for Baricitinib
Recently, drug manufacturer, Bajaj Healthcare Limited issued a press release stating that they have filed a compulsory license application with the Indian Patent Office seeking permission to manufacture both active pharmaceutical ingredients (raw materials) and formulation of Baricitinib under the Indian Patents Act. Baricitinib is essentially a drug approved in the US and European Union, … Continue reading Bajaj Healthcare Files Compulsory License with Indian Patent Office for Baricitinib
Read more »Elli Lilly Enters into Licensing Deals with Indian Companies
Recently, Elli Lilly, a US-based major Pharmaceutical company, has entered into licensing agreements with a number of Indian drug manufacturers for the manufacture of and supply of Baricitinib in India which is showing promise as a drug for the treatment of Covid-19. The licensing agreement with Eli Lilly is voluntary, royalty-free, and non-exclusive in nature … Continue reading Elli Lilly Enters into Licensing Deals with Indian Companies
Read more »Patents and Public Health
Introduction Patents and public health is the most relevant topic of discussion when the whole world is fighting against the global pandemic, Covid-19. It is no doubt that granting patent protection to a drug is important and serves many purposes, but can we put the lives of millions of people at stake in this time … Continue reading Patents and Public Health
Read more »Sunovion Pharmaceuticals and Bial Portela Files Patent Infringement Suit against A Host of Indian Drug Makers
Recently, The Bial – Portela & CA (“Bial”), a Portugal-based pharmaceutical company, and Sunovion Pharmaceuticals (“Sunvion”), a US-based pharmaceutical company have instituted suit of patent infringement against eight drug makers in the District Court of Delaware. The eight defendants are: Torrent Pharmaceuticals and Torrent Pharma Inc., Alkem Laboratories and S&B Pharma, Inc., Lupin Limited and … Continue reading Sunovion Pharmaceuticals and Bial Portela Files Patent Infringement Suit against A Host of Indian Drug Makers
Read more »Unboxing The Confusion In Marks Of Pharmaceutical Products
It is not new that the Supreme Court had cautiously laid down the seven principles for determining confusion or deceptiveness in pharmaceutical products. The landmark case of Cadilla held that medicines are boon but if given wrongly it can have life-threatening impact. Thus, there need not be an iota of confusion in the mind of … Continue reading Unboxing The Confusion In Marks Of Pharmaceutical Products
Read more »Combating Opioid Misuse – COMBAT (Curb Opioid Misuse By Advancing Technology Act of 2016)
The Congress recently introduced a bill on the COMBAT Act (Curb Opioid Misuse By Advancing Technology Act of 2016) to incentivize the development of abuse-deterrent opioids by amending the Federal Food, Drug, and Cosmetic Act to extend the exclusivity period for certain drug products developed or labeled so as to reduce drug abuse, and for … Continue reading Combating Opioid Misuse – COMBAT (Curb Opioid Misuse By Advancing Technology Act of 2016)
Read more »